Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orchid invests in Diakron

This article was originally published in Scrip

Executive Summary

Orchid Chemicals and Pharmaceuticalshas acquired majority control in Diakron Pharmaceuticals, the US drug development firm that has an exclusive licence for an investigational oral anticoagulant drug candidate discovered and developed through Phase I by Merck & Co. Diakron has the exclusive rights to develop, and, if approved, market and distribute the compound worldwide.

Topics

Related Companies

UsernamePublicRestriction

Register

SC005874

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel